Overview

This trial is active, not recruiting.

Condition diabetes mellitus, type i
Treatment islets
Phase phase 2
Sponsor Rodolfo Alejandro
Collaborator National Institutes of Health (NIH)
Start date December 2000
End date May 2019
Trial size 40 participants
Trial identifier NCT00306098, 2000/0196, HRSA # 1 R38OT01367-01-00, NIH #1U42 RR016603-01

Summary

SPECIFIC AIMS:

1. To reverse hyperglycemia and insulin dependency in patients with Type 1 Diabetes Mellitus by islet cell transplantation;

2. To eliminate the incidence of hypoglycemia coma and unawareness in patients with Type 1 Diabetes Mellitus by islet cell transplantation;

3. To assess long-term safety and function of successful islet cell transplants in patients with Type 1 Diabetes Mellitus;

4. To determine whether the natural history of the microvascular, macrovascular and neuropathic complications of Diabetes Mellitus are altered following successful transplantation of islet cells; and

5. To assess the effect of infliximab in preventing early islet destruction, and thereby eliminating the need for a second donor's islet cells.

6. To assess the effect of etanercept in preventing early islet destruction.

7. To assess the effect of exenatide to improve islet graft function and survival in subjects that have returned to using exogenous insulin.

8. To assess the ability of exenatide to improve islet survival at time of transplantation.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
islets
Islet transplantation

Primary Outcomes

Measure
a1c less than 6.5 without severe hypoglycemia
time frame: for the duration of islet graft function

Secondary Outcomes

Measure
Secondary end-points will include: partial graft function, as evidenced by baseline C-peptide greater than 0.5 ng/ml
time frame: for the duration of islet graft function
evidence for reduction in insulin requirements in those patients who do not achieve insulin independence
time frame: for the duration of islet graft function
improvement in metabolic control as evidenced by improvement in: HbA1C (should be < 7), mean amplitude of glycemic excursions (MAGE), mean glucose meter readings, continuous glucose monitoring, OGTT, and acute C-peptide response to arginine challenge
time frame: for the duration of islet graft function
elimination or reduction in the incidence of hypoglycemic coma or unawareness
time frame: for the duration of islet graft function
improvement in or decreased progression of microvascular, macrovascular and neuropathic complications of diabetes
time frame: for the duration of islet graft function
assessment of efficacy of infliximab in preventing early rejection - number of subjects achieving insulin independence with a single infusion
time frame: for the duration of islet graft function
assessment of efficacy of etanercept in preventing early rejection - number of subjects achieving insulin independence with a single infusion
time frame: for the duration of islet graft function
assessment of EXN to re-establish insulin independence or increase insulin secretion - reduction in insulin requirements with restoration of satisfactory glycemic control
time frame: for the duration of islet graft function
assessment of EXN to improve islet survival at time of islet transplantation - number of subjects achieving insulin independence with a single infusion
time frame: for the duration of islet graft function

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: 1. Patients between 18 and 65 years of age 2. Patients with type 1 diabetes mellitus for more than 5 years duration 3. One or more of the following: - Hypoglycemia unawareness - judged by history of blood sugars <54 on glucometer without symptoms and/or hypoglycemic episodes requiring assistance from either family, glucagon administration or emergency services - Poor diabetes control (HbA1c>8% or >2 visits/yr to hospital for treatment of ketoacidosis) despite intensive insulin therapy - Progressive complications of type 1 diabetes mellitus 4. Body Mass Index (BMI) ≤26 Exclusion Criteria: 1. c-peptide > 0.3ng/ml basal or stimulated; 2. untreated proliferative diabetic retinopathy; 3. HbA1C >12%; 4. creatinine clearance <60; 5. serum creatinine consistently >1.6 mg/dl; 6. macroalbuminuria >300mg albumin in 24 hours; 7. presence of panel reactive antibodies (PRA) >20%; 8. previous/concurrent organ transplantation (except previous unsuccessful islet cell transplant; 9. malignancy or previous malignancy (except non-melanomatous skin cancer); 10. x-ray evidence of pulmonary infection; 11. active infections; 12. active peptic ulcer disease, gall stones, hemangioma, or portal hypertension 13. serological evidence of HIV, HbsAg or HCV; serological evidence of active EBV (IgM>IgG) or EBV negative serology; 14. PPD conversion or positive PPD without historic completion of appropriate prophylactic treatment; 15. abnormal liver function test; 16. anemia (hemoglobin <12.0); 17. hyperlipidemia (fasting serum triglycerides >200mg/dl and/or fasting serum cholesterol >240 mg/dl and/or fasting LDL cholesterol >140 mg/dl); 18. BMI above 26; 19. unstable cardiovascular status; prostate specific antigen (PSA) >4; 20. pregnancy or breastfeeding; 21. sexually-active females who are not: a) post-menopausal, b) surgically sterile, or c) not using an acceptable method of contraception (oral contraceptives, Norplant, Depo-Provera, and barrier devices are acceptable; condoms used alone are not acceptable); 22. alcohol abuse, substance abuse or smoking within the previous 6 months; insulin requirement >1u/kg/day and any condition or any circumstance that makes it unsafe to undergo an islet cell transplant.

Additional Information

Official title Islet Cell Transplantation Alone in Patients With Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression
Principal investigator Rodolfo Alejandro, M.D.
Description This Phase II trial will have 3 groups: Group A will receive islets from 2 donors and will not receive infliximab. Group B will receive, in addition to Daclizumab, Sirolimus, and Tacrolimus, a dose of infliximab and islets from a single donor, as per the Edmonton protocol. Everything else about the clinical trial will be the same for both groups. The first 4 patients will be assigned to Group A, the next 4 patients to Group B, the next 4 patients to Group A, and the next 4 patients to Group B (total =16). Patients in Group A will receive 1-2 transplants with cells from 2 donors. If the second donor pancreas is received and satisfactory at the same time as the first pancreas, one islet infusion will be used to infuse cells from both donors. If the second pancreas is not received until after the first transplantation, a second islet infusion will be done. A second course of five doses of Daclizumab will be started on the day of the second islet infusion). In order to determine if prolonged administration of etanercept, in combination with transplantation of cultured islets, will prevent TNF-α production and enhance engraftment, we have added Group C to the current protocol. Group C, in addition to Daclizumab, Sirolimus, and Tacrolimus, will receive Etanercept in the peri-transplant period and islets from one or more donors. The last 24 patients included in this Protocol will be in Group C if they are new, or in Group A and B Supplemental Infusion if they had previous transplants. Any Group A or B participants who are eligible for a supplemental infusion will receive etanercept but no infliximab.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by University of Miami.